Xenon Pharmaceuticals Inc.
XENE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582313
In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.07M in total
- 2
- 13F holdersQ2 2026, +27 vs. previous quarter
- 315
- 13F valueReported value at the end of Q2 2026
- $6.10B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding XENE, Q2 2026
1 superinvestor reports holding Xenon Pharmaceuticals Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.3%
Xenon Pharmaceuticals Inc.'s share of the portfolio
- Shares
- 238,600
- Value
- $14.4M
Latest insider trades
Open-market purchases and sales by Xenon Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 (view filing)9:59 PM ET | Aug 28 | 3 days | Kenney Christopher JohnChief Medical Officer | SSale | −7.07K | $60.25 | −$425.8K | −100.0%2 after | 2 lots10b5-1 |
| Aug 13, 2026 (view filing)4:33 PM ET | Aug 11 | 2 days | Gannon StevenDirector | SSale | −10.0K | $64.06 | −$640.5K | −84.2%1.87K after | |
| Jun 8, 2026 (view filing) | Jun 5 | 3 days | Patou GaryDirector | SSale | −1.32K | $53.14 | −$70.3K | −5.0%24.9K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 5 | 3 days | Cannon GillianDirector | SSale | −1.19K | $53.14 | −$63.2K | −45.0%1.46K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Kenney Christopher JohnChief Medical Officer | SSale | −1.41K | $55.23 | −$77.9K | −16.6%7.07K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | DiFabio AndreaChief Legal Officer | SSale | −1.34K | $55.23 | −$74.1K | −15.5%7.30K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Mortimer IanPRESIDENT & CEO | SSale | −7.31K | $55.23 | −$403.6K | −26.8%19.9K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Kenney Christopher JohnChief Medical Officer | SSale | −2.77K | $60.11 | −$166.6K | −36.9%4.73K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | DiFabio AndreaChief Legal Officer | SSale | −2.61K | $60.11 | −$156.7K | −34.8%4.89K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 9-10 | 2 days | Mortimer IanPRESIDENT & CEO | SSale | −281.3K | $60.32 | −$17.0M | −95.0%14.7K after | 10 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Xenon Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,647,998 | $582.4M | 0.03% | −1,170,493−10.8% | Reduced |
| BlackRock, Inc. | 7,522,482 | $454.1M | 0.01% | +1,882,364+33.4% | Added |
| Avoro Capital Advisors LLC | 5,777,777 | $348.7M | 3.13% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 4,570,556 | $275.9M | 0.78% | +165,244+3.8% | Added |
| Driehaus Capital Management LLC | 4,418,557 | $266.7M | 1.55% | −73,096−1.6% | Reduced |
| Jupiter Topco LLC | 4,186,519 | $252.7M | 0.10% | +4,186,519 | New |
| Price T Rowe Associates Inc | 3,248,219 | $196.1M | 0.02% | +1,918,628+144.3% | Added |
| JPMorgan Chase & Co | 2,617,360 | $157.4M | 0.01% | +693,750+36.1% | Added |
| Capital International Investors | 2,361,639 | $142.5M | 0.03% | −313,088−11.7% | Reduced |
| T. Rowe Price Investment Management, Inc. | 2,168,581 | $130.9M | 0.09% | +1,216,626+127.8% | Added |